Pharmaceuticals
Activist Starboard Value has $1 billion Pfizer stake, taps former executives for help, sources say
People pass by the Pfizer headquarters building in New York City, Jan. 29, 2023. Kena Betancur | View Press | Corbis News | Getty Images Activist investor Starboard Value has a roughly $1 billion stake in pharmaceutical giant Pfizer and is seeking to mount a turnaround at the struggling company, according to people familiar with […]
Read More
CVS is under pressure and considering a break up. Here’s why that could be risky
A sign outside of a CVS pharmacy store on February 07, 2024 in Miami, Florida. Joe Raedle | Getty Images It’s time for a wellness check at CVS Health. Shares of the company are down more than 20% this year as it grapples with higher-than-expected medical costs in its insurance unit and pharmacy reimbursement pressure, […]
Read More
Port strike fallout: Blockbuster weight-loss drug supply from Wegovy to Ozempic, Mounjaro, Zepbound, caught up in East Coast trade shutdown
An Eli Lilly & Co. Zepbound injection pen, March 28, 2024. Bloomberg | Bloomberg | Getty Images As a port strike stretching from New England to Texas halted nearly half of all trade coming into the U.S., customs data shows that critical medical devices and drug components for the booming, expensive weight-loss and diabetes drugs […]
Read More
CVS is working with advisors on strategic review, sources say
CVS Pharmacy logo is seen in Washington DC, United States on July 9, 2024. Jakub Porzycki | Nurphoto | Getty Images CVS Health‘s board has engaged advisors to conduct a strategic review of its business, according to people familiar with the matter, as the company contends with potential activist pressure and a severely depressed stock […]
Read More
Major CVS shareholder plans activist push, will meet with management, sources say
CVS Pharmacy logo is seen at store in Florida Keys, United States on May 7, 2024. Jakub Porzycki | Nurphoto | Getty Images Glenview Capital, a major CVS Health shareholder, is expected to meet with company leadership on Monday to lay out proposed fixes for the struggling business, according to people familiar with the matter, […]
Read More
FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades
Bristol Myers Squibb’s Cobenfy drug Courtesy: Bristol Myers Squibb The Food and Drug Administration on Thursday approved Bristol Myers Squibb‘s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, […]
Read More
Novo Nordisk’s diabetes drug Ozempic may lower the risk of opioid overdoses, study says
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Novo Nordisk‘s blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative treatment for opioid use disorder, according to a new study […]
Read More
Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks during an interview in New York on Aug. 10, 2022. Christopher Goodney | Bloomberg | Getty Images Novo Nordisk‘s top executive is slated to face a Senate grilling on Tuesday over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic, as demand […]
Read More
Why Eli Lilly and Palo Alto Networks are both up on news from their competitors
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: The Dow and S & P 500 were lower Friday after surging to record highs Thursday in response to the Fed cutting interest rates by […]
Read More
FTC sues drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen use practices that boost their profits while “artificially” inflating costs for patients. The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts. All are […]
Read More